Discovery of a pyrimidine compound endowed with antitumor activity

Invest New Drugs. 2020 Feb;38(1):39-49. doi: 10.1007/s10637-019-00762-y. Epub 2019 Mar 21.

Abstract

Recently, some synthetic nitrogen-based heterocyclic molecules, such as PJ34, have shown pronounced antitumor activity. Therefore, we designed and synthesized new derivatives characterized by a nitrogen-containing scaffold and evaluated their antiproliferative properties in tumor cells. We herein report the effects of three newly synthesized compounds on cell lines from three different human cancers: triple-negative breast cancer, colon carcinoma and glioblastoma. We found that two of these compounds did not affect proliferation, while the third significantly inhibited replication of the three cell lines. Moreover, this third molecule at 20 μM led to the upregulation of p21 and p27 and blockage of the cell cycle at G0/G1; in addition, it induced apoptosis in all three cell lines when used at higher concentrations (30-50 μM). The results demonstrate that this compound is a potent inhibitor of replication, an inducer of apoptosis and a negative regulator of cell cycle progression for cancer cells of different histotypes. Our data suggest a potential role for this new molecule as an interesting and powerful tool for new approaches in treating various cancers.

Keywords: Breast cancer; Colon carcinoma; Glioblastoma multiforme; PJ34; Phenathridinone; Pyrimidine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Apoptosis
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Cell Cycle
  • Cell Line, Tumor
  • Cell Proliferation
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / pathology
  • Drug Discovery*
  • Drug Screening Assays, Antitumor
  • Female
  • Glioblastoma / drug therapy*
  • Glioblastoma / pathology
  • Humans
  • Pyrimidines / chemistry*
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • Pyrimidines